Literature DB >> 17532463

Inflammatory response in preeclampsia.

Barbara Schiessl1.   

Abstract

The origin of preeclampsia, a disease unique to pregnancy is still matter of debate and numerous theories have been proposed. The pathophysiology of the disease involves impaired trophoblast invasion, abnormal genetic polymorphism, vascular endothelial cell activation, immune intolerance by the maternal immune system, but also an exaggeration of a systemic inflammatory process. Preeclampsia is one of the major causes of maternal and perinatal morbidities including preterm births and therefore merits ongoing intensive research. The inflammatory process is determined by immunogenetic and non-immunogenetic factors. While inflammation mostly appears to be related to immunogenic determinants such as HLA antigens, paternity, monocytes, proinflammatory cytokines and NK cells, also responses not directly related to the immune system have been observed such as related to hypoxia or agonistic autoantibodies directed against vasoconstrictive angiotensin II receptors. The HIF-modulated reactions open up a new field in research as recently published data show the complexity of these factors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17532463     DOI: 10.1016/j.mam.2007.04.004

Source DB:  PubMed          Journal:  Mol Aspects Med        ISSN: 0098-2997


  24 in total

1.  Recent insights into the pathophysiology of preeclampsia.

Authors:  Eric M George; Joey P Granger
Journal:  Expert Rev Obstet Gynecol       Date:  2010-09-01

2.  TREM-1 expression is increased in human placentas from severe early-onset preeclamptic pregnancies where it may be involved in syncytialization.

Authors:  Ratana Lim; Gillian Barker; Martha Lappas
Journal:  Reprod Sci       Date:  2013-09-11       Impact factor: 3.060

Review 3.  Inflammation in reproductive disorders.

Authors:  Gerson Weiss; Laura T Goldsmith; Robert N Taylor; Dominique Bellet; Hugh S Taylor
Journal:  Reprod Sci       Date:  2009-02       Impact factor: 3.060

Review 4.  Endothelin: key mediator of hypertension in preeclampsia.

Authors:  Eric M George; Joey P Granger
Journal:  Am J Hypertens       Date:  2011-06-16       Impact factor: 2.689

5.  Magnesium decreases inflammatory cytokine production: a novel innate immunomodulatory mechanism.

Authors:  Jun Sugimoto; Andrea M Romani; Alice M Valentin-Torres; Angel A Luciano; Christina M Ramirez Kitchen; Nicholas Funderburg; Sam Mesiano; Helene B Bernstein
Journal:  J Immunol       Date:  2012-05-18       Impact factor: 5.422

6.  Tissue factor activity in women with preeclampsia or SGA: a potential explanation for the excessive thrombin generation in these syndromes.

Authors:  Offer Erez; Roberto Romero; Edi Vaisbuch; Nandor Gabor Than; Juan Pedro Kusanovic; Shali Mazaki-Tovi; Francesca Gotsch; Pooja Mittal; Zhong Dong; Tinnakorn Chaiworapongsa; Chong Jai Kim; Chia-Ling Nhan-Chang; Sun Kwon Kim; Lami Yeo; Moshe Mazor; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2017-05-19

7.  Aberrant synthesis, metabolism, and plasma accumulation of circulating estrogens and estrogen metabolites in preeclampsia implications for vascular dysfunction.

Authors:  Sheikh O Jobe; Chanel T Tyler; Ronald R Magness
Journal:  Hypertension       Date:  2013-01-14       Impact factor: 10.190

8.  Disturbed sleep and inflammatory cytokines in depressed and nondepressed pregnant women: an exploratory analysis of pregnancy outcomes.

Authors:  Michele L Okun; James F Luther; Stephen R Wisniewski; Katherine L Wisner
Journal:  Psychosom Med       Date:  2013-07-17       Impact factor: 4.312

Review 9.  The functional role of the renin-angiotensin system in pregnancy and preeclampsia.

Authors:  R A Irani; Y Xia
Journal:  Placenta       Date:  2008-08-08       Impact factor: 3.481

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.